PROS1 and atrial fibrillation: Antivitamin K oral anticoagulants (AKOA) function by reducing plasma concentrations of the vitamin-K-dependent proteins (FII, FVII, FIX, FX, protein C, and protein S) and are crucial in the pharmacological treatment of cardiac and thromboembolic disorders, as well as atrial fibrillation [1].